Upward analyst revisions for Arcutis Biotherapeutics reflect stronger-than-expected product sales, accelerating prescription growth, and optimism over Zoryve’s potential broader indications, lifting the consensus price target from $21.86 to $22.75.
Analyst Commentary
- Bullish analysts highlighted Arcutis's stronger-than-expected total product sales and robust 19% quarter-over-quarter prescription growth, with stable gross-to-net (GTN) in the 50% range.
- Near-term growth is anticipated from commercial execution and the potential for indication expansion of its lead product, Zoryve.
- Zoryve life-cycle management and the potential to target over 40 inflammatory dermatology indications are expected to support mid-term revenue expansion.
- Pipeline advancement and potential business development (BD) opportunities are cited as key drivers for long-term growth.
- Some caution remains as large brokerage observes Zoryve’s favorable dermatologist profile but notes future growth may be constrained, awaiting further clarity on the asset before turning more constructive.
What's in the News
- New data presented at EADV Congress show ZORYVE (roflumilast) foam 0.3% significantly improves seborrheic dermatitis across diverse skin types, races, and ethnicities, with efficacy demonstrated in subgroup analyses.
- ZORYVE cream 0.3% is FDA-approved for plaque psoriasis (patients 6+), while cream 0.15% is approved for mild to moderate atopic dermatitis (patients 6+); both have received awards and positive recognition within the dermatology community.
- Arcutis submitted a supplemental New Drug Application to the FDA to expand ZORYVE cream 0.3% for plaque psoriasis in children as young as age 2, supported by favorable safety and efficacy data.
- ZORYVE cream 0.15% received a strong recommendation in the American Academy of Dermatology guideline update for adult atopic dermatitis, highlighting its efficacy, tolerability, and low discontinuation rates as a non-steroidal treatment option.
Valuation Changes
Summary of Valuation Changes for Arcutis Biotherapeutics
- The Consensus Analyst Price Target has risen slightly from $21.86 to $22.75.
- The Future P/E for Arcutis Biotherapeutics has risen slightly from 14.37x to 14.96x.
- The Discount Rate for Arcutis Biotherapeutics remained effectively unchanged, at 6.78%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.